

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	SRF IN
Equity Shares (m)	296
M.Cap.(INRb)/(USDb)	868 / 10.2
52-Week Range (INR)	3099 / 2089
1, 6, 12 Rel. Per (%)	-8/29/20
12M Avg Val (INR M)	1685

#### Financials & Valuations (INR b)

Y/E Mar	2025	2026E	2027E
Sales	146.9	173.4	205.0
EBITDA	28.4	37.5	49.3
PAT	13.7	21.1	29.3
EBITDA (%)	19.3	21.6	24.0
EPS (INR)	46.1	70.9	98.7
EPS Gr. (%)	(3.0)	54.0	39.1
BV/Sh. (INR)	424	478	560

#### Ratios

Net D/E	0.3	0.3	0.2
RoE (%)	11.4	15.7	19.0
RoCE (%)	9.6	12.6	15.2
Payout (%)	35.7	24.0	17.2

#### Valuations

P/E (x)	63.5	41.2	29.6
EV/EBITDA (x)	31.9	24.2	18.4
Div Yield (%)	0.5	0.6	0.6
FCF Yield (%)	1.4	0.7	0.9

#### Shareholding Pattern (%)

As On	Mar-25	Dec-24	Mar-24
Promoter	50.3	50.3	50.3
DII	18.5	17.8	16.0
FII	18.3	18.4	19.1
Others	13.0	13.6	14.6

Note: FII includes depository receipts

**CMP: INR2,928 TP: INR3,500 (+20%) Buy**

### Chemicals segment resilient and continues to grow

#### Operating performance above our estimates

- SRF posted a strong overall performance in 4QFY25, with its EBIT rising 53% YoY, led by a 3.2x/50% YoY surge in packaging film/chemical businesses.
- Despite macroeconomic headwinds due to rising geopolitical tensions, SRF remained resilient and improved its performance in 2HFY25, with revenue/EBITDA/Adj. PAT surging 20%/41%/30% YoY in 4QFY25.
- We earlier upgraded the stock following its 3QFY25 results, fueled by an anticipated demand recovery in the specialty chemical business and strong traction in the fluorochemicals business. We expect this momentum to sustain going forward. Management has also guided a healthy 20%+ growth in the chemicals business, with EBIT margin in the range of 25-26% (+/- 2%), indicating a strong momentum for FY26.
- We broadly maintain our FY26/FY27 EBITDA estimates and **reiterate our BUY rating**, valuing the stock on an SoTP basis to arrive at our **TP of INR3,500**.

#### Margin improvements in Chemicals and Packaging drive performance

- SRF reported an overall revenue of INR43b (in line) in 4QFY25, up ~21% YoY. EBITDA margin expanded 330bp YoY to 23.2% (est. of 21.4%). EBITDA stood at INR10b (est. of INR8.9b), up 41% YoY. Adj. PAT grew 30% YoY to INR5.7b (est. of INR4.7b), adjusted for a forex loss of INR451m in 4QFY25.
- **Chemicals'** revenue (55%/83% of total sales/EBIT in 4QFY25) grew 30% YoY to INR23.5b, while EBIT grew 50% YoY to INR7.4b. EBIT margin expanded 440bp YoY to 31.8%. The specialty chemicals business demonstrated strong performance, driven by positive momentum in recently launched products and a pick-up in demand for certain key agrochemical intermediates, while the fluorochemicals business reported higher volumes and realizations.
- **Packaging film's** revenue (33%/12% of total sales/EBIT in 4QFY25) grew 19% YoY to INR14.1b, while EBIT grew 3.2x YoY to INR1b. Margin expanded 460bp YoY to 7.4%. The packaging films business witnessed healthy growth driven by higher volumes and realizations for both BOPP and BOPET, with margin expansion fueled by the ramping up of value-added products.
- **Technical textiles'** revenue (11%/4% of total sales/EBIT in 4QFY25) was down 2% YoY to INR4.5b. EBIT dipped 43% YoY to INR401m. EBIT margin contracted 600bp YoY to 8.7%. The technical textiles business underperformed because of continued weak demand and margins in belting fabrics.

#### Highlights from the management commentary

- **Chemicals business:** Management is targeting over 20% revenue growth in FY26, with 2HFY26 expected to outperform 1HFY26 due to seasonality factors. The company is aiming for >INR110b revenue over the next three years. Further, the overall chemical business's EBIT margin is projected to be in the range of ~25-26% (+/- 2%) in FY26.

Research Analyst: **Sumant Kumar** (Sumant.Kumar@MotilalOswal.com) | **Meet Jain** (Meet.Jain@MotilalOswal.com)

Research Analyst: **Nirvik Saini** (Nirvik.Saini@MotilalOswal.com) | **Yash Darak** (Yash.darak@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **Packaging business:** The Board approved the establishment of a new BOPP PE film line in Indore, with an investment of INR4.45b and an additional 50-55 KPTA of new capacity. Going forward, the company will continue to focus on increasing the sales of high-impact VAP.
- **Capex:** For FY26, the company has plans to incur a capex of ~INR22b-23b, with the possibility of an increase during the year. SRF witnessed a 30% rise in overall capacity by taking up small debottlenecking activity over the last 18 months.

### Valuation and view

- The chemicals business (fluorochemicals and specialty chemicals) is expected to continue the growth momentum in FY26, led by a strong order book in the specialty business and ramp-up of export volumes, coupled with growth in PTFE within the fluorochemicals business. The packaging business is experiencing improvement in the near term, led by increasing focus on high-impact VAPs.
- We build in revenue/EBITDA/Adj. PAT CAGR of 18%/32%/46% over FY25-27E. We broadly maintain our estimates and reiterate **our BUY** rating, valuing the stock on an SoTP basis to arrive at our TP of INR3,500.

### Consolidated - Quarterly Earnings Model


Y/E March	FY24				FY25				FY24	FY25	FY25E	(INR m)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4Q	Var %
<b>Net Sales</b>	<b>33,384</b>	<b>31,774</b>	<b>30,530</b>	<b>35,697</b>	<b>34,641</b>	<b>34,243</b>	<b>34,913</b>	<b>43,133</b>	<b>131,385</b>	<b>146,931</b>	<b>41,608</b>	<b>4</b>
YoY Change (%)	-14.3	-14.8	-12.0	-5.5	3.8	7.8	14.4	20.8	-11.6	11.8	16.6	
Total Expenditure	26,184	25,320	24,691	28,581	28,435	28,637	28,375	33,108	104,777	118,555	32,693	
<b>EBITDA</b>	<b>7,200</b>	<b>6,453</b>	<b>5,839</b>	<b>7,116</b>	<b>6,207</b>	<b>5,606</b>	<b>6,538</b>	<b>10,025</b>	<b>26,608</b>	<b>28,376</b>	<b>8,916</b>	<b>12</b>
Margins (%)	21.6	20.3	19.1	19.9	17.9	16.4	18.7	23.2	20.3	19.3	21.4	
Depreciation	1,566	1,612	1,689	1,859	1,882	1,939	1,943	1,952	6,726	7,715	2,100	
Interest	656	793	674	900	965	938	963	894	3,023	3,760	940	
Other Income	118	291	188	234	253	333	396	345	830	1,327	350	
<b>PBT before EO expense</b>	<b>5,095</b>	<b>4,339</b>	<b>3,664</b>	<b>4,591</b>	<b>3,612</b>	<b>3,063</b>	<b>4,029</b>	<b>7,525</b>	<b>17,689</b>	<b>18,229</b>	<b>6,226</b>	
Extra-Ord expense & DO	237	191	181	158	172	226	342	451	767	1,192	0	
<b>PBT</b>	<b>4,858</b>	<b>4,148</b>	<b>3,483</b>	<b>4,433</b>	<b>3,440</b>	<b>2,837</b>	<b>3,687</b>	<b>7,074</b>	<b>16,922</b>	<b>17,037</b>	<b>6,226</b>	
Tax	1,265	1,140	949	211	918	822	976	1,813	3,565	4,529	1,526	
Rate (%)	24.8	26.3	25.9	4.6	25.4	26.9	24.2	24.1	20.2	24.8	24.5	
<b>Reported PAT</b>	<b>3,593</b>	<b>3,008</b>	<b>2,534</b>	<b>4,222</b>	<b>2,522</b>	<b>2,014</b>	<b>2,711</b>	<b>5,261</b>	<b>13,357</b>	<b>12,508</b>	<b>4,700</b>	
<b>Adj PAT</b>	<b>3,830</b>	<b>3,199</b>	<b>2,715</b>	<b>4,380</b>	<b>2,695</b>	<b>2,240</b>	<b>3,053</b>	<b>5,712</b>	<b>14,124</b>	<b>13,700</b>	<b>4,700</b>	<b>22</b>
YoY Change (%)	-39.5	-38.1	-48.4	-25.8	-29.6	-30.0	12.4	30.4	-37.7	-3.0	7	
Margins (%)	11.5	10.1	8.9	12.3	7.8	6.5	8.7	13.2	10.8	9.3	11.3	

## Key Performance Indicators

Y/E March	FY24E				FY25E				FY24	FY25
Consolidated	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
Segment Revenue (INRm)										
Technical Textile	4,647	5,062	4,584	4,689	5,253	5,355	5,098	4,584	18,980	20,291
Chemicals	16,605	14,263	13,941	18,161	14,820	13,578	14,957	23,553	62,970	66,908
Packaging Film	10,948	11,215	10,907	11,824	13,363	14,206	13,848	14,122	44,893	55,538
Others	1,187	1,269	1,136	1,062	1,262	1,128	1,011	874	4,653	4,275
Segment Revenue Growth (%)										
Technical Textile	-18.6	8.6	7.6	8.9	13.1	5.8	11.2	-2.2	0.2	
Chemicals	-3.6	-22.1	-20.6	-13.6	-10.8	-4.8	7.3	29.7	-15.0	6.9
Packaging Film	-26.8	-15.7	-9.3	2.5	22.1	26.7	27.0	19.4	-13.4	6.3
Other	12.4	26.4	23.0	12.6	6.3	-11.1	-10.9	-17.6	18.5	23.7
Segment Results (INRm)										-8.1
Technical Textile	607	750	688	698	677	713	589	401	2,742	
Chemicals	4,601	3,478	3,219	4,977	3,064	2,461	3,638	7,485	16,274	
Packaging Film	513	773	449	331	868	828	904	1,046	2,065	2,381
Others	232	331	212	156	236	172	157	124	930	16,648
Segment EBIT Margins (%)										3,645
Technical Textile	13.1	14.8	15.0	14.9	12.9	13.3	11.6	8.7	14.4	688
Chemicals	27.7	24.4	23.1	27.4	20.7	18.1	24.3	31.8	25.8	
Packaging Film	4.7	6.9	4.1	2.8	6.5	5.8	6.5	7.4	4.6	
Others	19.5	26.1	18.7	14.7	18.7	15.2	15.5	14.2	20.0	11.7
Cost Break-up										24.9
RM Cost (% of sales)	50.9	51.0	50.9	51.4	52.7	53.6	51.7	51.8	51.1	6.6
Staff Cost (% of sales)	6.5	7.1	8.0	6.9	7.3	7.4	7.5	6.4	7.1	16.1
Power and Fuel Cost (% of sales)	10.6	10.8	10.5	9.2	9.9	10.1	9.5	7.7	10.2	
Other Cost (% of sales)	10.4	10.7	11.5	12.6	12.2	12.6	12.6	10.9	11.3	
Gross Margins (%)	49.1	49.0	49.1	48.6	47.3	46.4	48.3	48.2	48.9	52.4
EBITDA Margins (%)	21.6	20.3	19.1	19.9	17.9	16.4	18.7	23.2	20.3	7.1
EBIT Margins (%)	16.9	15.2	13.6	14.7	12.5	10.7	13.2	18.7	15.1	9.2


## Key Exhibits

**Exhibit 1: Consolidated revenue trend**




Source: Company, MOFSL

**Exhibit 2: Consolidated EBITDA trend**




Source: Company, MOFSL

**Exhibit 3: Consolidated adjusted PAT trend**




Source: Company, MOFSL

**Exhibit 4: Revenue mix trend**




Source: Company, MOFSL

**Exhibit 5: EBIT mix trend**




Source: Company, MOFSL

**Exhibit 6: Revenue trend in the Chemicals business**




Source: Company, MOFSL

**Exhibit 7: EBIT trend in the Chemicals business**




Source: Company, MOFSL

**Exhibit 8: Revenue trend in the Packaging Film business**




Source: Company, MOFSL

**Exhibit 9: EBIT trend in the Packaging Film business**




Source: Company, MOFSL

**Exhibit 10: Revenue trend in the Technical Textiles business**



Source: Company, MOFSL

**Exhibit 11: EBIT trend in the Technical Textiles business**



Source: Company, MOFSL



## Key highlights from the management commentary

### Chemicals business: Specialty chemicals

- The specialty chemicals segment delivered strong revenue and margin growth YoY mainly led by the strong traction in the recently launched products and the recovery in off-take of certain key agrochemical intermediates
- SRF continues its focus on strengthening the product pipeline and ramping up newly commissioned plants
- Successfully launched five new agro products and three new pharma products in FY25
- SRF undertook debottlenecking of capacity across several products and multiple campaigns in MPPs with an investment of INR7b, enhancing future capabilities, leading to a 30% increase in overall capacity
- The pricing pressure from Chinese competitors continued, leading to price adjustments for multiple products
- Raw materials have started showing signs of stabilization
- Management is targeting 20%+ revenue growth in FY26 and building strong momentum in the years ahead, with an aim of INR110b+ revenue in the next three years
- 2HFY26 is expected to surpass 1HFY26, led by some factor of seasonality in this estimate
- Volumes are expected to be better for both the businesses in 1HFY26, along with better volumes for legacy products with incremental volumes from new products
- The overall chemical business EBIT margins are expected to be in the range of ~25-26% (+/- 2%) going ahead, led by healthy volumes and better product mix
- The pharma segment contributed to ~6-7% revenue share in FY25
- Export currently stands for ~70-71% in the specialty chemicals business

### Chemicals: Fluorochemicals

- Fluorochemicals business reported strong performance in 4QFY25, driven by the higher volumes and realizations of HFCs across domestic and export markets, along with record domestic sales of ref gases, driven by the highest-ever R32 production and offtake.
- Demand for Dymel continued to see strong traction.
- With the rising demand for refrigerants due to increased AC and automobile production in India, SRF maintains its dominant share in the domestic Room Air Conditioners (RAC) and Mobile Air Conditioners (MAC) markets.
- Mandate for in-cabin AC for Commercial vehicles is expected to further drive ref gas consumption, with India and the Middle East expected to drive future growth for Ref gas
- Reduced Chinese HFC supplies resulting in increased global prices
- Increased competition and the oversupply situation in the domestic chloromethane market are adversely impacting margins
- Inventory levels in the US have decreased
- PTFE is showing early signs of improvement, with the ramp-up fully expected in FY26

- The ongoing capex of INR11b will be completed within 30 months from the date of approval.
- No major impact was witnessed, neither negative nor positive from the India-UK FTA.
- The pricing trends for FY26 are as follows: R32 pricing is still expected to fluctuate, R134A is anticipated to remain flat with a slight positive trend, R125 is expected to stay flat, and R22 pricing is experiencing an increase.
- Capacity utilization for HFC is expected to increase significantly in FY26, rising to 80-85% from 70% in FY25.

#### **Packaging film business**

- Performance Films & Foil Business witnessed healthy revenue growth, driven by higher volume and realizations for both BOPP and BOPET, and margin expansion led by continued focus on ramping up value-added products.
- Demand-supply balance for BOPP stands better than BOPET, and the capacity utilization in India has improved for both BOPP and BOPET.
- SRF launched 12 new products in FY25: 5 in BOPET and 7 in BOP
- Performance of Aluminum foil witnessed a positive change over 3Q, led by higher export volume, while the domestic demand for aluminium foil remained subdued
- The board has approved the establishment of a new capacity of BOPP PE film line in Indore during the year, with an investment of INR4.45b and is expected to commence in ~ 25 months from the date of approval
- An additional 50-55 KPTA of new capacity is expected to be introduced in this segment.
- The subsidiaries, primarily involved in the packaging film business in Hungary and aluminum foil business, are currently facing a PAT loss in Hungary but expect a positive PAT in FY26, with both subsidiaries being profitable at the EBITDA level.
- Going ahead, the company will continue its focus on increasing the sales of the high-impact VAP

#### **Technical textiles business:**

- Technical textiles business declined by 2% YoY in 4QFY25 due to Weak demand and increased competition from low-cost Chinese imports in Belting Fabrics, while the margins were impacted by the lower margins in Nylon Tyre Cord Fabrics
- Achieved the highest-ever production and sales in FY25 of Tyre Cord Fabrics, Polyester Industrial Yarn, and belting fabrics
- Maintained dominant position in the domestic Belting Fabrics market with sequential growth in exports
- The management expects the belting fabrics' performance to improve with increased government spending, revival of tier II markets, and higher exports, along with a rebound in cement, steel, and coal production and round construction in FY26
- FY26 is expected to deliver performance similar to that of FY25.

### Others

- Chances of seeing global growth slowing down with the company continuing to navigate through uncertain times
- The prices for each gas are expected to fluctuate differently.
- SRF plans to incur capex in the range of INR22b to INR23b for the FY26, with the possibility of an increase during the year.
- SRF expects the benefit of reduced borrowing costs in FY26 due to global interest rates trending downward.
- The company plans to optimize raw material sourcing as part of its cost-saving initiatives in the future.
- The management believes it will be able to maintain or increase its market share in the chemicals business, regardless of the situation in China.
- Strong demand is anticipated for both coated and laminated fabrics going forward.

### Valuation and view

- The chemicals business (fluorochemicals and specialty chemicals) is expected to continue the growth momentum in FY26, led by a strong order book in the specialty business and ramp-up of export volumes, coupled with growth in PTFE within the fluorochemicals business. The packaging business is experiencing improvement in the near term, led by increasing focus on high-impact VAPs.
- We build in revenue/EBITDA/Adj. PAT CAGR of 18%/32%/46% over FY25-27E. We broadly maintain our estimates and reiterate **our BUY** rating, valuing the stock on an SoTP basis to arrive at our TP of INR3,500.

### Exhibit 12: Valuation methodology

EV/EBITDA	FY27 EBITDA (INRm)	Multiple (x)	EV (INRm)
Technical Textiles	4,759	12	59,253
Chemicals	35,928	25	913,465
Packaging Films	10,886	12	135,318
Others	1,154	10	12,005
<b>Total EV</b>			<b>1,085,812</b>
Less: Debt			52,412
Less: Minority Interest			-
Add: Cash & Cash Equivalents			7,638
<b>Target Mcap (INR m)</b>			<b>1,041,037</b>
Outstanding Share (m)			297.4
<b>Target Price (INR)</b>			<b>3,500</b>

Source: MOFSL

### Exhibit 13: Revisions to our estimates

Earnings Change (INR m)	Old		New		Change (%)	
	FY26E	FY27E	FY26E	FY27E	FY27E	FY27E
Revenue	176,613	209,090	173,402	205,050	-2	-2
EBITDA	38,542	50,557	37,527	49,302	-3	-2
Adj. PAT	21,310	29,774	21,100	29,344	-1	-1

Source: MOFSL

## Financials and valuations

Consolidated - Income Statement							(INRm)	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Income from Operations	72,094	84,000	124,337	148,703	131,385	146,931	173,402	205,050
Less: Excise Duty	0	0	0	0	0	0	0	0
<b>Total Income from Operations</b>	<b>72,094</b>	<b>84,000</b>	<b>124,337</b>	<b>148,703</b>	<b>131,385</b>	<b>146,931</b>	<b>173,402</b>	<b>205,050</b>
Change (%)	1.5	16.5	48.0	19.6	-11.6	11.8	18.0	18.3
<b>Total Expenditure</b>	<b>57,510</b>	<b>62,667</b>	<b>93,305</b>	<b>112,371</b>	<b>104,777</b>	<b>118,555</b>	<b>135,876</b>	<b>155,748</b>
% of Sales	79.8	74.6	75.0	75.6	79.7	80.7	78.4	76.0
<b>EBITDA</b>	<b>14,584</b>	<b>21,333</b>	<b>31,032</b>	<b>36,332</b>	<b>26,608</b>	<b>28,376</b>	<b>37,527</b>	<b>49,302</b>
Margin (%)	20.2	25.4	25.0	24.4	20.3	19.3	21.6	24.0
Depreciation	3,886	4,531	5,172	5,753	6,726	7,715	8,443	9,619
<b>EBIT</b>	<b>10,698</b>	<b>16,803</b>	<b>25,860</b>	<b>30,579</b>	<b>19,882</b>	<b>20,661</b>	<b>29,084</b>	<b>39,682</b>
Int. and Finance Charges	2,007	1,340	1,159	2,048	3,023	3,760	2,663	2,571
Other Income	491	545	428	749	830	1,327	1,526	1,755
<b>PBT bef. EO Exp.</b>	<b>9,182</b>	<b>16,008</b>	<b>25,128</b>	<b>29,280</b>	<b>17,689</b>	<b>18,229</b>	<b>27,948</b>	<b>38,867</b>
EO Items	997	116	727	-1,040	-767	-1,192	0	0
<b>PBT after EO Exp.</b>	<b>10,179</b>	<b>16,123</b>	<b>25,856</b>	<b>28,240</b>	<b>16,922</b>	<b>17,037</b>	<b>27,948</b>	<b>38,867</b>
Current Tax	265	4,154	7,139	6,617	3,565	4,544	6,848	9,523
Deferred Tax	-277	-10	-173	0	0	-14	0	0
Tax Rate (%)	-0.1	25.7	26.9	23.4	21.1	26.6	24.5	24.5
Less: Minority Interest	0	0	0	0	0	0	0	0
<b>Reported PAT</b>	<b>10,191</b>	<b>11,979</b>	<b>18,889</b>	<b>21,623</b>	<b>13,357</b>	<b>12,508</b>	<b>21,100</b>	<b>29,344</b>
<b>Adjusted PAT</b>	<b>9,194</b>	<b>11,864</b>	<b>18,162</b>	<b>22,663</b>	<b>14,124</b>	<b>13,700</b>	<b>21,100</b>	<b>29,344</b>
Change (%)	49.4	29.0	53.1	24.8	-37.7	-3.0	54.0	39.1
Margin (%)	12.8	14.1	14.6	15.2	10.8	9.3	12.2	14.3

Consolidated - Balance Sheet							(INRm)	
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	585	603	2,974	2,974	2,974	2,974	2,974	2,974
Total Reserves	48,748	67,962	82,679	100,296	111,816	123,288	139,331	163,618
<b>Net Worth</b>	<b>49,333</b>	<b>68,564</b>	<b>85,654</b>	<b>103,271</b>	<b>114,790</b>	<b>126,262</b>	<b>142,305</b>	<b>166,592</b>
Minority Interest	0	0	0	0	0	0	0	0
Deferred Liabilities	1,755	3,862	6,775	8,092	9,387	10,553	10,553	10,553
Total Loans	40,468	33,950	35,394	43,541	49,202	46,412	50,412	52,412
<b>Capital Employed</b>	<b>91,556</b>	<b>106,376</b>	<b>127,822</b>	<b>154,903</b>	<b>173,380</b>	<b>183,227</b>	<b>203,271</b>	<b>229,558</b>
Gross Block	76,934	96,167	106,943	128,622	167,373	180,146	200,146	233,146
Less: Accum. Deprn.	15,540	20,071	25,243	30,997	37,723	45,438	53,880	63,499
<b>Net Fixed Assets</b>	<b>61,394</b>	<b>76,096</b>	<b>81,699</b>	<b>97,626</b>	<b>129,650</b>	<b>134,708</b>	<b>146,266</b>	<b>169,646</b>
Goodwill on Consolidation	6	6	0	0	0	0	0	0
Capital WIP	13,933	7,723	16,716	24,055	8,053	8,110	11,110	6,110
Current Investments	1,985	4,125	3,167	4,901	4,056	7,045	7,045	7,045
<b>Total Investments</b>	<b>2,027</b>	<b>4,167</b>	<b>3,209</b>	<b>4,942</b>	<b>5,267</b>	<b>8,273</b>	<b>8,273</b>	<b>8,273</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>31,265</b>	<b>41,121</b>	<b>56,025</b>	<b>60,735</b>	<b>61,574</b>	<b>64,123</b>	<b>73,498</b>	<b>86,397</b>
Inventory	12,012	14,658	21,385	22,743	23,265	23,490	26,302	30,302
Account Receivables	8,911	12,746	17,925	17,856	19,428	21,695	23,754	28,089
Cash and Bank Balance	1,255	2,820	4,594	6,165	4,075	3,538	5,731	7,638
Loans and Advances	9,088	10,898	12,123	13,972	14,805	15,401	17,711	20,368
<b>Curr. Liability &amp; Prov.</b>	<b>17,211</b>	<b>22,918</b>	<b>29,944</b>	<b>32,642</b>	<b>31,440</b>	<b>32,344</b>	<b>36,233</b>	<b>41,226</b>
Account Payables	11,117	15,852	20,964	22,313	21,978	23,316	26,302	30,302
Other Current Liabilities	5,653	6,544	8,391	9,642	8,660	8,104	8,914	9,806
Provisions	442	522	590	687	802	924	1,017	1,118
<b>Net Current Assets</b>	<b>14,054</b>	<b>18,203</b>	<b>26,081</b>	<b>28,093</b>	<b>30,134</b>	<b>31,779</b>	<b>37,265</b>	<b>45,171</b>
Deferred Tax assets	143	181	116	187	276	357	357	357
Misc Expenditure	0	0	0	0	0	0	0	0
<b>Appl. of Funds</b>	<b>91,556</b>	<b>106,376</b>	<b>127,822</b>	<b>154,903</b>	<b>173,380</b>	<b>183,227</b>	<b>203,271</b>	<b>229,558</b>

## Financials and valuations

### Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Basic (INR)</b>								
<b>EPS</b>	<b>30.9</b>	<b>39.9</b>	<b>61.1</b>	<b>76.2</b>	<b>47.5</b>	<b>46.1</b>	<b>70.9</b>	<b>98.7</b>
Cash EPS	44.0	55.1	78.5	95.5	70.1	72.0	99.3	131.0
BV/Share	165.9	230.5	288.0	347.2	385.9	424.5	478.4	560.1
DPS	2.8	4.9	16.8	7.2	7.2	15.0	17.0	17.0
Payout (%)	9.6	12.1	26.4	9.9	16.0	35.7	24.0	17.2
<b>Valuation (x)</b>								
P/E	95	73	48	38	62	64	41	30
Cash P/E	67	53	37	31	42	41	29	22
P/BV	18	13	10	8	8	7	6	5
EV/Sales	13	11	7	6	7	6	5	4
EV/EBITDA	62	42	29	25	34	32	24	18
Dividend Yield (%)	0.1	0.2	0.6	0.2	0.2	0.5	0.6	0.6
FCF per share	-2.3	19.1	9.7	0.0	-6.1	40.5	19.9	25.3
<b>Return Ratios (%)</b>								
RoE	20.3	20.1	23.6	24.0	13.0	11.4	15.7	19.0
RoCE	13.3	13.4	17.2	17.9	10.5	9.6	12.6	15.2
RoIC	15.3	26.3	34.2	34.7	18.2	17.4	22.3	26.8
<b>Working Capital Ratios</b>								
Fixed Asset Turnover (x)	0.9	0.9	1.2	1.2	0.8	0.8	0.9	0.9
Asset Turnover (x)	0.8	0.8	1.0	1.0	0.8	0.8	0.9	0.9
Inventory (Days)	119	133	129	112	127	111	108	108
Debtor (Days)	45	55	53	44	54	54	50	50
Creditor (Days)	110	144	126	110	120	111	108	108
Working Cap. Turnover (Days)	65	67	63	54	72	70	66	67
<b>Leverage Ratio (x)</b>								
Current Ratio	1.8	1.8	1.9	1.9	2.0	2.0	2.0	2.1
Interest Cover Ratio	5	13	22	15	7	5	11	15
Debt/Equity	0.8	0.5	0.4	0.4	0.4	0.4	0.4	0.3

### Consolidated - Cash Flow Statement

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	10,706	16,099	25,856	28,240	16,922	17,037	27,948	38,867
Depreciation	3,929	4,531	5,172	5,753	6,726	7,715	8,443	9,619
Interest & Finance Charges	2,016	1,340	1,159	2,048	3,023	3,760	2,663	2,571
Direct Taxes Paid	-1,427	-2,553	-4,016	-6,617	-3,565	-4,544	-6,848	-9,523
(Inc)/Dec in WC	-239	-1,236	-6,645	-408	-2,168	906	-3,293	-5,999
<b>CF from Operations</b>	<b>14,984</b>	<b>18,181</b>	<b>21,527</b>	<b>29,017</b>	<b>20,938</b>	<b>24,875</b>	<b>28,912</b>	<b>35,535</b>
Others	-1,940	-464	-469	0	0	0	0	0
<b>CF from Operating incl EO</b>	<b>13,044</b>	<b>17,717</b>	<b>21,057</b>	<b>29,017</b>	<b>20,938</b>	<b>24,875</b>	<b>28,912</b>	<b>35,535</b>
(inc)/dec in FA	-13,730	-12,047	-18,171	-29,019	-22,748	-12,830	-23,000	-28,000
<b>Free Cash Flow</b>	<b>-685</b>	<b>5,670</b>	<b>2,886</b>	<b>-2</b>	<b>-1,810</b>	<b>12,044</b>	<b>5,912</b>	<b>7,535</b>
(Pur)/Sale of Investments	-886	-1,886	1,028	-1,733	-325	-3,006	0	0
Others	2,813	-1,064	1,265	1,138	800	996	0	0
<b>CF from Investments</b>	<b>-11,803</b>	<b>-14,997</b>	<b>-15,877</b>	<b>-29,614</b>	<b>-22,273</b>	<b>-14,840</b>	<b>-23,000</b>	<b>-28,000</b>
Issue of Shares	0	7,500	2	0	0	0	0	0
Inc/(Dec) in Debt	3,205	-6,856	622	8,147	5,662	-2,790	4,000	2,000
Interest Paid	-2,040	-1,574	-1,173	-2,048	-3,023	-3,760	-2,663	-2,571
Dividend Paid	-803	-1,408	-2,117	-2,142	-2,142	-4,462	-5,056	-5,056
Others	-2,337	1,182	-741	-1,789	-1,252	439	0	0
<b>CF from Fin. Activity</b>	<b>-1,975</b>	<b>-1,155</b>	<b>-3,406</b>	<b>2,168</b>	<b>-754</b>	<b>-10,572</b>	<b>-3,719</b>	<b>-5,627</b>
<b>Inc/Dec of Cash</b>	<b>-734</b>	<b>1,565</b>	<b>1,774</b>	<b>1,571</b>	<b>-2,089</b>	<b>-538</b>	<b>2,193</b>	<b>1,907</b>
Opening Balance	1,989	1,255	2,820	4,594	6,164	4,075	3,538	5,731
<b>Closing Balance</b>	<b>1,255</b>	<b>2,820</b>	<b>4,594</b>	<b>6,164</b>	<b>4,075</b>	<b>3,538</b>	<b>5,731</b>	<b>7,638</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajan@motilaloswal.com](mailto:nainesh.rajan@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.